Spojené státy - angličtina - NLM (National Library of Medicine)

strides pharma science limited - tranylcypromine sulfate (unii: 7zat6es870) (tranylcypromine - unii:3e3v44j4z9) - tranylcypromine sulfate is indicated for the treatment of major depressive disorder (mdd) in adult patients who have not responded adequately to other antidepressants. tranylcypromine sulfate is not indicated for the initial treatment of mdd due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [see contraindications (4), warnings and precautions (5), and drug interactions (7)] . concomitant use of tranylcypromine sulfate or use in rapid succession with the products in table 1 is contraindicated. such use may cause severe or life-threatening reactions such as hypertensive crises or serotonin syndrome [see drug interactions (7.1)]. medication-free periods between administration of tranylcypromine sulfate and contraindicated agents are recommended [see dosage and administration (2.2) and drug interactions (7.1)]. - other monoamine oxidase inhibitors (maois) - selective serotonin reuptake inhibitors (ssris) and serotonin and norepinephrine reuptake inhi

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - tranylcypromine sulfate - oral tablet - 10mg